Skip to main content

Drug Interactions between Aleve and Duexis

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ibuprofen naproxen

Applies to: Duexis (famotidine / ibuprofen) and Aleve (naproxen)

GENERALLY AVOID: Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy. Patients with a prior history of peptic ulcer disease and/or GI bleeding have a greater than 10-fold increased risk of developing a GI bleed during NSAID use compared to patients without a history. Additional risk factors include old age, alcohol use, smoking, and poor general health status.

MANAGEMENT: Concomitant use of more than one NSAID at a time should generally be avoided. Some authorities consider the concomitant use of more than one NSAID at a time to be contraindicated due to the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions (AU,UK). Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.

References

  1. (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
  2. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  3. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  4. (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
  5. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  6. (2001) "Product Information. Daypro (oxaprozin)." Searle
  7. (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
  8. (2006) "Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group
  9. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  10. Cerner Multum, Inc. "Australian Product Information."
  11. (2009) "Product Information. Cambia (diclofenac)." Kowa Pharmaceuticals America (formerly ProEthic)
  12. (2009) "Product Information. Caldolor (ibuprofen)." Cumberland Pharmaceuticals Inc
  13. (2010) "Product Information. VIMOVO (esomeprazole-naproxen)." Astra-Zeneca Pharmaceuticals
  14. (2011) "Product Information. Duexis (famotidine-ibuprofen)." Horizon Therapeutics USA Inc
  15. (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
  16. (2016) "Product Information. Etodolac ER (etodolac)." Taro Pharmaceuticals U.S.A. Inc
  17. (2016) "Product Information. Ketoprofen ER (ketoprofen)." Mylan Pharmaceuticals Inc
View all 17 references

Switch to consumer interaction data

Moderate

naproxen famotidine

Applies to: Aleve (naproxen) and Duexis (famotidine / ibuprofen)

GENERALLY AVOID: The concomitant administration of H2 blockers may increase the dissolution rate of enteric-coated naproxen, causing the drug to be released in the stomach instead of the small intestine.

MANAGEMENT: H2 antagonists should be avoided in patients taking enteric-coated formulations of naproxen.

References

  1. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc

Switch to consumer interaction data

Minor

ibuprofen famotidine

Applies to: Duexis (famotidine / ibuprofen) and Duexis (famotidine / ibuprofen)

H2 antagonists may alter the disposition of nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data are varied, even for the same NSAID. The mechanism may be related to inhibition of metabolism, changes in gastric pH that decrease absorption, and/or reduced urinary elimination. Statistically significant changes have been small and of limited clinical significance. Clinical monitoring of patient response and tolerance is recommended.

References

  1. Said SA, Foda AM (1989) "Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man." Arzneimittelforschung, 39, p. 790-2
  2. Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS (1986) "Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine." Eur J Clin Pharmacol, 31, p. 371-4
  3. (2001) "Product Information. Daypro (oxaprozin)." Searle

Switch to consumer interaction data

Drug and food interactions

Moderate

ibuprofen food

Applies to: Duexis (famotidine / ibuprofen)

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Switch to consumer interaction data

Moderate

naproxen food

Applies to: Aleve (naproxen)

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Switch to consumer interaction data

Minor

famotidine food

Applies to: Duexis (famotidine / ibuprofen)

H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.

References

  1. Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9

Switch to consumer interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Nonsteroidal anti-inflammatories

Therapeutic duplication

The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category:

  • Aleve (naproxen)
  • Duexis (famotidine/ibuprofen)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer